Jakob, Jens

[["dc.bibliographiccitation.firstpage","10554"],["dc.bibliographiccitation.issue","15, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Menge, Franka"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Mathew, Monika"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Reichardt, Peter"],["dc.contributor.author","Wardelmann, Eva"],["dc.date.accessioned","2020-11-23T13:33:34Z"],["dc.date.available","2020-11-23T13:33:34Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1200/jco.2014.32.15_suppl.10554"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69010"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution radiation therapy for disease control"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","301"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","312"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Golcher, Henriette"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Richter, Stephan"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2021-06-01T09:42:10Z"],["dc.date.available","2021-06-01T09:42:10Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development."],["dc.identifier.doi","10.1159/000516262"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85163"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e009558"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Dimitrakopoulou-Strauss, Antonia"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Nowak, Kai"],["dc.contributor.author","Pilz, Lothar R."],["dc.contributor.author","Attenberger, Ulrike"],["dc.contributor.author","Gaiser, Timo"],["dc.contributor.author","Egerer, Gerlinde"],["dc.contributor.author","Fröhling, Stefan"],["dc.contributor.author","Derigs, Hans-Günter"],["dc.contributor.author","Schwarzbach, Matthias"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:32:57Z"],["dc.date.available","2020-11-23T13:32:57Z"],["dc.date.issued","2016-01-06"],["dc.description.abstract","For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. Since surgery is often complicated by large tumour size and extensive tumour vasculature, preoperative treatment strategies with the aim of devitalising the tumour are being explored. One option is treatment with antiangiogenic drugs. The multikinase inhibitor pazopanib, which possesses pronounced antiangiogenic effects, has shown activity in metastatic and unresectable STS, but has so far not been tested in the preoperative setting."],["dc.identifier.doi","10.1136/bmjopen-2015-009558"],["dc.identifier.pmid","26739732"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69004"],["dc.language.iso","en"],["dc.relation.issn","2044-6055"],["dc.title","Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","87"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","94"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Galata, Christian"],["dc.contributor.author","Wimmer, Elisabeth"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Wenz, Frederik"],["dc.contributor.author","Reißfelder, Christoph"],["dc.contributor.author","Jakob, Jens"],["dc.date.accessioned","2020-11-23T13:31:54Z"],["dc.date.available","2020-11-23T13:31:54Z"],["dc.date.issued","2019"],["dc.description.abstract","The treatment of oligometastatic disease is challenging and few data exist to guide treatment decisions. The objective of this study was to improve the data on the prevalence and treatment of patients with oligometastatic disease."],["dc.identifier.doi","10.1159/000495474"],["dc.identifier.pmid","30814474"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68989"],["dc.language.iso","en"],["dc.relation.eissn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Onkologe"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hornemann, Beate"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Arndt, Karin"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-04-01T10:02:16Z"],["dc.date.available","2022-04-01T10:02:16Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung Hintergrund Knochensarkome sind eine Gruppe sehr seltener maligner Tumoren. Es existieren nur wenige Studien zur psychischen Belastung der betroffenen Patienten. Ziel war es, die Prävalenz erhöhter psychischer Belastung in dieser Gruppe zu ermitteln, damit assoziierte Faktoren zu untersuchen und die Inanspruchnahme psychoonkologischer Angebote zu erfassen. Methode Die Kohortenstudie PROSa (Krankheitslast und Versorgungssituation bei Sarkomen) wurde zwischen 2017 und 2020 in 39 deutschen Studienzentren durchgeführt. Für die vorliegende Analyse wurden Baseline-Querschnittsdaten von erwachsenen Knochensarkompatienten ausgewertet. Die psychische Belastung wurde mit dem Patient Health Questionnaire (PHQ-4) evaluiert. Sozioökonomische und klinische Faktoren wurden als mögliche Prädiktoren erhöhter psychischer Belastung mit multivariablen logistischen Regressionsmodellen exploriert. Resultate Bei den 194 eingeschlossenen Patienten betrug die Prävalenz von Ängsten 18 %, die von Depressivität 22 %. Insgesamt waren 29 % der Patienten überschwellig psychisch belastet. 23 % hatten eine psychoonkologische Betreuung in Anspruch genommen. Im vollen Modell waren arbeitslose Patienten (Odds Ratio [OR] 5,7; 95 %-Konfidenzintervall [CI] 1,6–20,0) und Patienten mit Erwerbsminderungsrente (OR 3,6; 95 %-CI 1,03–12,9) im Vergleich zu solchen in Beschäftigung häufiger belastet, Patienten mit Altersrente, in Vorruhestand oder in Altersteilzeit dagegen weniger häufig (OR 0,2; 95 %-CI 0,05–0,9). Die Häufigkeit psychischer Belastung war bei Patienten 5 Jahre nach Diagnose (Vergleich Diagnose < 6 Monate) geringer (OR 0,1; 95 %-CI 0,04–0,4). Konklusion Die Prävalenz erhöhter psychischer Belastung bei Knochensarkompatienten ist hoch. Arbeitslose Patienten, solche mit Erwerbsminderungsrente sowie neu diagnostizierte Patienten sind besonders vulnerabel. Das Behandlungsteam sollte sich dieser Faktoren bewusst sein und auch diese sozialen Aspekte der Erkrankung berücksichtigen."],["dc.identifier.doi","10.1007/s00761-022-01098-8"],["dc.identifier.pii","1098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105869"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1433-0415"],["dc.relation.issn","0947-8965"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Psychische Verfassung und psychosoziale Versorgungssituation von Patienten mit Knochensarkomen"],["dc.title.alternative","Resultate einer deutschen multizentrischen Beobachtungsstudie (PROSa)"],["dc.title.translated","Psychological distress and psychosocial treatment situation in patients with bone sarcomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","British Journal of Cancer"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Richter, Stephan"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Grützmann, Robert"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-02-01T10:31:08Z"],["dc.date.available","2022-02-01T10:31:08Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment."],["dc.description.abstract","Abstract Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1038/s41416-022-01702-z"],["dc.identifier.pii","1702"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98790"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.relation.eissn","1532-1827"],["dc.relation.issn","0007-0920"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","pon.6009"],["dc.bibliographiccitation.journal","Psycho-Oncology"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hornemann, Beate"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Arndt, Karin"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-09-01T09:50:29Z"],["dc.date.available","2022-09-01T09:50:29Z"],["dc.date.issued","2022"],["dc.description.sponsorship"," Deutsche Krebshilfe https://doi.org/10.13039/501100005972"],["dc.identifier.doi","10.1002/pon.6009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113723"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1099-1611"],["dc.relation.issn","1057-9249"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Distress in soft‐tissue sarcoma and gastrointestinal stromal tumours patients—Results of a German multicentre observational study (PROSa)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","639"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Biology"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Gaiser, Timo"],["dc.contributor.author","Sauer, Christian"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Hirsch, Daniela"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.date.accessioned","2021-09-01T06:43:07Z"],["dc.date.available","2021-09-01T06:43:07Z"],["dc.date.issued","2021"],["dc.description.abstract","In the framework of the German Interdisciplinary Sarcoma Group GISG-04/NOPASS trial, we evaluated soft tissue sarcoma samples taken before and after neoadjuvant pazopanib therapy using histopathology and next generation sequencing (NGS) to find potential predictive biomarkers. We also aimed to improve the genetically based sarcoma classification and to elucidate additional potentially druggable mutations. In total, 30 tumor samples from 18 patients consisting of 12 pre-therapeutic biopsies and 18 resection specimens following neoadjuvant pazopanib therapy were available for analyses. NGS was performed with the Oncomine Focus Assay (Ion Torrent) covering 0.03 Mb of DNA and enabled the detection of genetic variants in 52 cancer-relevant genes. Pathological analysis showed significant regression (≥50%) after pazopanib treatment in only one undifferentiated (pleomorphic) sarcoma. NGS analyses revealed a very high frequency of CDK4 amplification (88%; 7/8) in the group of dedifferentiated liposarcoma. In addition, two potentially druggable mutations, a MAP2K1 missense mutation (E203K) and a BRAF missense mutation (V600E), were traceable in two undifferentiated (pleomorphic) sarcoma patients (11%; 2/18). Our findings demonstrate that NGS testing is a powerful technology helping to improve diagnostic accuracy and offering some patients the chance for personalized medicine even in a “mutation unlikely” cohort like STS."],["dc.description.abstract","In the framework of the German Interdisciplinary Sarcoma Group GISG-04/NOPASS trial, we evaluated soft tissue sarcoma samples taken before and after neoadjuvant pazopanib therapy using histopathology and next generation sequencing (NGS) to find potential predictive biomarkers. We also aimed to improve the genetically based sarcoma classification and to elucidate additional potentially druggable mutations. In total, 30 tumor samples from 18 patients consisting of 12 pre-therapeutic biopsies and 18 resection specimens following neoadjuvant pazopanib therapy were available for analyses. NGS was performed with the Oncomine Focus Assay (Ion Torrent) covering 0.03 Mb of DNA and enabled the detection of genetic variants in 52 cancer-relevant genes. Pathological analysis showed significant regression (≥50%) after pazopanib treatment in only one undifferentiated (pleomorphic) sarcoma. NGS analyses revealed a very high frequency of CDK4 amplification (88%; 7/8) in the group of dedifferentiated liposarcoma. In addition, two potentially druggable mutations, a MAP2K1 missense mutation (E203K) and a BRAF missense mutation (V600E), were traceable in two undifferentiated (pleomorphic) sarcoma patients (11%; 2/18). Our findings demonstrate that NGS testing is a powerful technology helping to improve diagnostic accuracy and offering some patients the chance for personalized medicine even in a “mutation unlikely” cohort like STS."],["dc.description.sponsorship","Novartis"],["dc.description.sponsorship","GlaxoSmithKline"],["dc.description.sponsorship","Medical Faculty of the Martin-Luther-University Halle-Wittenberg"],["dc.identifier.doi","10.3390/biology10070639"],["dc.identifier.pii","biology10070639"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89223"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.publisher","MDPI"],["dc.relation.eissn","2079-7737"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2839"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Surgical Oncology"],["dc.bibliographiccitation.lastpage","2845"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Simeonova, Anna"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Wenz, Frederik"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:33:07Z"],["dc.date.available","2020-11-23T13:33:07Z"],["dc.date.issued","2015-09"],["dc.description.abstract","Antiangiogenic substances and radiation therapy (RT) may have synergistic effects and improve irradiation efficacy. We present a cohort study evaluating the toxicity of combined sunitinib and RT as neoadjuvant treatment of extremity and retroperitoneal soft tissue sarcoma (STS)."],["dc.identifier.doi","10.1245/s10434-015-4680-3"],["dc.identifier.pmid","26085221"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69006"],["dc.language.iso","en"],["dc.relation.eissn","1534-4681"],["dc.relation.issn","1068-9265"],["dc.title","Combined radiation therapy and sunitinib for preoperative treatment of soft tissue sarcoma"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1332"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Annals of Surgical Oncology"],["dc.bibliographiccitation.lastpage","1339"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Karampinis, Ioannis"],["dc.contributor.author","Dimitrakopoulou-Strauss, Antonia"],["dc.contributor.author","Sachpekidis, Christos"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Nowak, Kai"],["dc.contributor.author","Pilz, Lothar"],["dc.contributor.author","Attenberger, Ulrike"],["dc.contributor.author","Gaiser, Timo"],["dc.contributor.author","Derigs, Hans-Günther"],["dc.contributor.author","Schwarzbach, Matthias"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:31:40Z"],["dc.date.available","2020-11-23T13:31:40Z"],["dc.date.issued","2019-05"],["dc.description.abstract","Preoperative devascularization might improve local control and thus the outcome of patients with soft tissue sarcoma (STS). The multikinase inhibitor pazopanib has antiangiogenic effects and is approved for treating metastatic STS. We conducted a trial of preoperative pazopanib therapy in high-risk STS."],["dc.identifier.doi","10.1245/s10434-019-07183-4"],["dc.identifier.pmid","30843160"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68986"],["dc.language.iso","en"],["dc.relation.eissn","1534-4681"],["dc.relation.issn","1068-9265"],["dc.title","Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04)"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]